enGene Therapeutics (ENGN) Payables (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Payables of $2.0 million for Q2 2026, down 61.34% year-over-year from $5.1 million in Q2 2025, and down 24.29% quarter-over-quarter from $2.6 million in Q1 2026.
enGene Therapeutics (ENGN) Payables (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Payables for 5 consecutive years, with $2.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Payables fell 61.34% year-over-year to $2.0 million; the TTM figure through Apr 2026 stood at $2.0 million (down 61.34% YoY), while the FY2025 annual figure was $14.7 million, up 596.21% from the prior year.
- Payables fell to $2.0 million in Q2 2026 per ENGN's latest filing, from $2.6 million in the prior quarter.
- Across five years, Payables topped out at $40.0 million in Q3 2023 and bottomed at $211000.0 in Q2 2024.
- Historically, Payables has averaged $6.8 million across 5 years, with a median of $2.6 million in 2026.
- Annual changes were most pronounced in 2024 — Payables sank 89.49% — and 2025, when it soared 2334.6%.
- enGene Therapeutics' Payables stood at $2.0 million in 2022, then declined by 13.58% to $1.7 million in 2023, then increased by 22.82% to $2.1 million in 2024, then surged by 596.21% to $14.7 million in 2025, then plunged by 86.48% to $2.0 million in 2026.
- Business Quant data shows ENGN's Payables at $2.0 million in Q2 2026, $2.6 million in Q1 2026, and $14.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 35.57 Mn |
| 10 | enGene Therapeutics | 123.41 Mn | 123.41 Mn | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.99 Mn |
| Jan 31, 2026 | 2.62 Mn |
| Oct 31, 2025 | 14.69 Mn |
| Jul 31, 2025 | 7.80 Mn |
| Apr 30, 2025 | 5.14 Mn |
| Jan 31, 2025 | 4.30 Mn |
| Oct 31, 2024 | 2.11 Mn |
| Jul 31, 2024 | 4.20 Mn |
| Apr 30, 2024 | 211,000.00 |
| Jan 31, 2024 | 1.28 Mn |
| Oct 31, 2023 | 1.72 Mn |
| Jul 31, 2023 | 39.99 Mn |
| Oct 31, 2022 | 1.99 Mn |